TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

New developments for antibody-drug conjugate-based therapeutic approaches

(2016) Bart ECG de Goeij et al.   CURRENT OPINION IN IMMUNOLOGY

Opportunities and challenges for TCR mimic antibodies in cancer therapy

(2016) Aaron Y. Chang et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Intracellular recycling and cross-presentation by MHC class I molecules

(2016) Peter van Endert   IMMUNOLOGICAL REVIEWS

Solid-Phase Synthesis of Duocarmycin Analogues and the Effect of C-Terminal Substitution on Biological Activity

(2015) Michael J. Stephenson et al.   JOURNAL OF ORGANIC CHEMISTRY

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

(2015) M. M. C. van der Lee et al.   MOLECULAR CANCER THERAPEUTICS

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

(2015) Ronald C. Elgersma et al.   MOLECULAR PHARMACEUTICS

Current ADC Linker Chemistry

(2015) Nareshkumar Jain et al.   PHARMACEUTICAL RESEARCH

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Intracellular Transport Routes for MHC I and Their Relevance for Antigen Cross-Presentation

(2015) Aimé Cézaire Adiko et al.   Frontiers in Immunology

T cell receptor mimic antibodies for cancer therapy

(2015) Leonid Dubrovsky et al.   OncoImmunology

Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

(2014) N. Veomett et al.   CLINICAL CANCER RESEARCH

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells

(2014) Giovanna Bossi et al.   OncoImmunology

Pathways of Antigen Processing

(2013) Janice S. Blum et al.   Annual Review of Immunology

Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody

(2013) M. Yoshikawa et al.   BLOOD

Antibody–drug conjugates: current status and future directions

(2013) Heidi L. Perez et al.   DRUG DISCOVERY TODAY

Targeting HER2+ breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles

(2013) Shawn C. Owen et al.   JOURNAL OF CONTROLLED RELEASE

Antitumor Activity of a Monoclonal Antibody Targeting Major Histocompatibility Complex Class I–Her2 Peptide Complexes

(2013) Rinki Jain et al.   JNCI-Journal of the National Cancer Institute

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

(2013) Michael Ritchie et al.   mAbs

Maturing antibody–drug conjugate pipeline hits 30

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer

(2012) N. P. Withana et al.   CANCER RESEARCH

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1–Her2341–456 fusion protein

(2011) Qiang Fu et al.   Cellular & Molecular Immunology

An Antibody-Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma

(2011) J. Asundi et al.   CLINICAL CANCER RESEARCH

TCR-like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells

(2011) Jon A. Weidanz et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Early endosomal rerouting of major histocompatibility class I conformers

(2011) Gordana Blagojević Zagorac et al.   JOURNAL OF CELLULAR PHYSIOLOGY

TCR Mimic Monoclonal Antibodies Induce Apoptosis of Tumor Cells via Immune Effector-Independent Mechanisms

(2011) B. Verma et al.   JOURNAL OF IMMUNOLOGY

An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer

(2011) O. Hawkins et al.   JOURNAL OF IMMUNOLOGY

In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

(2011) X. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties

(2009) Bhavna Verma et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Intracellular Assembly and Trafficking of MHC Class I Molecules

(2009) Julie G. Donaldson et al.   TRAFFIC

Antitumor Activity of Immunotoxins with T-Cell Receptor-like Specificity against Human Melanoma Xenografts

(2008) E. Klechevsky et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies

(2008) Malka Epel et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

How a T Cell Receptor-like Antibody Recognizes Major Histocompatibility Complex-bound Peptide

(2008) Tatiana Mareeva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY